Sunshine Biopharma (SBFM) Competitors $1.68 +0.01 (+0.30%) Closing price 04:00 PM EasternExtended Trading$1.66 -0.02 (-1.19%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SBFM vs. PMN, DARE, GLTO, KZR, CVKD, LPTX, ENLV, XCUR, QTTB, and TAOXShould you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include Promis Neurosciences (PMN), Dare Bioscience (DARE), Galecto (GLTO), Kezar Life Sciences (KZR), Cadrenal Therapeutics (CVKD), Leap Therapeutics (LPTX), Enlivex Therapeutics (ENLV), Exicure (XCUR), Q32 Bio (QTTB), and Synaptogenix (TAOX). These companies are all part of the "pharmaceutical products" industry. Sunshine Biopharma vs. Its Competitors Promis Neurosciences Dare Bioscience Galecto Kezar Life Sciences Cadrenal Therapeutics Leap Therapeutics Enlivex Therapeutics Exicure Q32 Bio Synaptogenix Sunshine Biopharma (NASDAQ:SBFM) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Do insiders and institutionals have more ownership in SBFM or PMN? 42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 0.1% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 6.1% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, SBFM or PMN? Sunshine Biopharma has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Is SBFM or PMN more profitable? Promis Neurosciences has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.35%. Sunshine Biopharma's return on equity of -26.04% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Sunshine Biopharma-17.35% -26.04% -20.72% Promis Neurosciences N/A -266.69%-131.59% Does the media prefer SBFM or PMN? In the previous week, Promis Neurosciences had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 2 mentions for Promis Neurosciences and 1 mentions for Sunshine Biopharma. Promis Neurosciences' average media sentiment score of 1.45 beat Sunshine Biopharma's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Overall Sentiment Sunshine Biopharma Neutral Promis Neurosciences Positive Do analysts rate SBFM or PMN? Sunshine Biopharma presently has a consensus target price of $7.00, indicating a potential upside of 316.67%. Promis Neurosciences has a consensus target price of $4.33, indicating a potential upside of 660.77%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than Sunshine Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Promis Neurosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better valuation and earnings, SBFM or PMN? Promis Neurosciences has lower revenue, but higher earnings than Sunshine Biopharma. Promis Neurosciences is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSunshine Biopharma$34.87M0.22-$5.13M-$150.88-0.01Promis NeurosciencesN/AN/A$2.78M-$0.21-2.71 SummaryPromis Neurosciences beats Sunshine Biopharma on 10 of the 14 factors compared between the two stocks. Get Sunshine Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBFM vs. The Competition Export to ExcelMetricSunshine BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.63M$3.37B$6.10B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-0.0121.7185.5527.59Price / Sales0.22477.40621.78138.47Price / CashN/A47.6737.7861.77Price / Book0.1810.1413.136.76Net Income-$5.13M-$52.31M$3.30B$275.88M7 Day Performance9.09%6.72%5.29%3.72%1 Month Performance19.15%15.01%9.94%10.22%1 Year Performance-42.86%29.34%87.78%35.86% Sunshine Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBFMSunshine Biopharma2.303 of 5 stars$1.68+0.3%$7.00+316.7%-44.5%$7.63M$34.87M-0.013Analyst ForecastPMNPromis Neurosciences3.1304 of 5 stars$0.55+0.6%$4.33+685.0%-50.8%$30.62MN/A-2.715News CoveragePositive NewsAnalyst ForecastGap UpDAREDare Bioscience1.9506 of 5 stars$2.24-0.7%$10.00+347.4%-32.1%$30.21M$10K-1.0530Positive NewsAnalyst ForecastGap UpGLTOGalecto0.8885 of 5 stars$21.16+470.5%$10.00-52.7%+111.7%$29.00MN/A-1.6740Trending NewsGap DownHigh Trading VolumeKZRKezar Life Sciences3.5592 of 5 stars$3.89-1.1%$9.00+131.7%-50.1%$28.45MN/A-0.4060Analyst ForecastHigh Trading VolumeCVKDCadrenal Therapeutics2.4404 of 5 stars$13.68+1.1%$32.00+133.9%+13.4%$28.04MN/A-1.544Analyst ForecastLPTXLeap Therapeutics2.6595 of 5 stars$0.67-11.9%$3.38+401.5%-73.7%$27.64MN/A-0.4240Analyst ForecastHigh Trading VolumeENLVEnlivex Therapeutics2.2071 of 5 stars$1.14-0.9%$10.00+781.1%-26.1%$27.57MN/A-1.9670Analyst ForecastXCURExicure1.7333 of 5 stars$4.21-1.5%N/A+52.8%$26.58M$500K-1.0850Analyst ForecastGap UpQTTBQ32 Bio2.9286 of 5 stars$2.15-1.2%$12.17+467.2%-94.2%$26.47M$1.16M-0.5039Gap UpTAOXSynaptogenix0.0585 of 5 stars$7.36-4.5%N/AN/A$25.69MN/A-0.374Analyst ForecastGap Up Related Companies and Tools Related Companies PMN Competitors DARE Competitors GLTO Competitors KZR Competitors CVKD Competitors LPTX Competitors ENLV Competitors XCUR Competitors QTTB Competitors TAOX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBFM) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersTesla’s $30 trillion pivotCircle Nov 6 – huge Tesla news? Tesla could be about to change forever. On November 6, insiders are warning...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
